4D Molecular Therapeutics (FDMT) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

FDMT 4D Molecular Therapeutics

Watchlist

4.580
-0.100-2.14%

Close Jan 17 16:00 ET

4.580
0.0000.00%

Post 20:01 ET

211.72MMarket Cap-1.61P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Leerink Partners Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Cuts Target Price to $27
Moomoo NewsJan 13 13:31 ET · Ratings
4D Molecular Therapeutics Is Maintained at Outperform by Leerink Partners
Dow JonesJan 13 11:23 ET · Ratings
Express News | Morgan Stanley Maintains Underweight on 4D Molecular Therapeutics, Lowers Price Target to $6
BenzingaJan 13 11:15 ET
4D Molecular Downgraded at BMO on Limited Population for Wet AMD Candidate
Seeking AlphaJan 13 09:26 ET
H.C. Wainwright Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Maintains Target Price $36
Moomoo NewsJan 13 07:34 ET · Ratings
HC Wainwright & Co. Reiterates Buy on 4D Molecular Therapeutics, Maintains $36 Price Target
BenzingaJan 13 07:00 ET · Ratings

Comments

Jaguar8

Jan 10 07:04

NEWS

$4D Molecular Therapeutics (FDMT.US)$
4DMT Announces Positive Interim Data from 4D-150 SPECTRA Clinical Trial in DME and Alignment with FDA on Registrational Path
3 minutes ago, 5:00 AM PST
Via GlobeNewswire
FDMT
Share
• Across all DME patients dosed to date, 4D-150 continues to be well tolerated with no intraocular inflammation observed at any timepoint or dose level
• 3E10 vg/eye demonstrated strong signals of clinical activity with sustained gain of BCVA of +8.4 letters and reduction of ...

北美深蓝

Jul 23, 2024 20:31

$4D Molecular Therapeutics (FDMT.US)$
🌈 静待股价回落，长线标的，观察仓开仓目标价14.85
⭕ Regulation FD Disclosure.
On July 23, 2024, 4D Molecular Therapeutics, Inc. (the “Company”) reported that interim longest available follow up data from the Phase 1 Dose Expansion cohort, Phase 2 Dose Expansion cohort, and Phase 2 Population Extension cohort from its Phase 1/2 PRISM clinical trial evaluating intravitreal 4D-150 in wet age-related macular degeneration are expected to be presented at a medical conference in Septemb...

Meltyy

May 16, 2024 01:19

🔔 RA Capital Q1 ‘24* Holdings Released... 🐳

» Holdings: 75
» Holdings in Top 20: 70.21%
» Qtr over Qtr Change**: +21.81%
Top Holdings:
$Ascendis Pharma A/S (ASND.US)$
$Vaxcyte (PCVX.US)$
$Legend Biotech (LEGN.US)$
$Janux Therapeutics (JANX.US)$
$Aerovate (AVTE.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Evolent Health (EVH.US)$
$NewAmsterdam Pharma (NAMS.US)$
$RxSight (RXST.US)$
$TYRA BIOSCIENCES, INC. (TYRA.US)$
$Edgewise Therapeutics (EWTX.US)$
$4D Molecular Therapeutics (FDMT.US)$
$Biogen (BIIB.US)$
$PepGen (PEPG.US)$
...

Lexyko

Feb 5, 2024 10:15

$4D Molecular Therapeutics (FDMT.US)$ should I buy?

Lexyko

Feb 5, 2024 08:23

$4D Molecular Therapeutics (FDMT.US)$ didnt know it jump so much..sold too early

Heat List

Overall

No Data